Arrowhead Pharmaceuticals stock reacts to index reshuffle and EU drug approval

Arrowhead Pharmaceuticals (ARWR) has been in focus after multiple Russell index changes on June 27 and a recent European Commission marketing authorization for its triglyceride lowering drug REDEMPLO for adults with familial chylomicronemia syndrome.

Arrowhead Pharmaceuticals shares have been strong recently, with a 1-day share price return of 4.41%, a 30-day share price return of 14.91%, and a 1-year total shareholder return above 400%. This suggests that momentum has been building around the index reshuffle and EU approval.

If this kind of momentum catches your eye, it may be worth broadening your watchlist through a curated list of 40 healthcare AI stocks.

With Arrowhead Pharmaceuticals now in larger indexes, a recent EU drug approval and an intrinsic value estimate implying a roughly 60% discount, the key question is whether the stock is still undervalued or if markets are already pricing in future growth.

Most Popular Narrative: 24% Undervalued

On the most followed narrative, Arrowhead Pharmaceuticals screens as undervalued, with a fair value of $110 against a last close of $83.99, which puts the current share price at a clear discount to those assumptions.

The company's capability to regularly advance 3 to 4 new wholly-owned drug candidates into the clinic every year, backed by a now-proven, modular multi-organ RNAi delivery platform, gives Arrowhead a unique capacity to continuously expand and diversify its pipeline, laying the foundation for compounding, multi-product revenue streams that substantially amplify long-term earnings power and valuation.

Curious what kind of revenue climb and margin shift would need to sit behind a $110 fair value and a premium future earnings multiple? The most popular narrative leans on a tight set of ambitious growth, profitability and valuation assumptions that are all spelled out in black and white, but only if you are ready to see how far the forecasts stretch.

Result: Fair Value of $110 (UNDERVALUED)

However, you still need to weigh the risk that Arrowhead Pharmaceuticals' heavy trial spend, ongoing net losses, and concentrated RNAi pipeline could quickly pressure funding needs and sentiment if setbacks appear.

Another View on Arrowhead Pharmaceuticals' Valuation

The most followed Arrowhead Pharmaceuticals narrative leans on a discounted cash flow outcome that screens the stock as undervalued, yet the current market pricing tells a more cautious story. At $83.99, shares trade only about 6% below the US$89.08 analyst price target, which suggests less obvious upside on that measure.

This gap between a wide DCF discount and a much tighter analyst target raises a practical question for investors: which signal should carry more weight in your own work?

Next Steps

Given the mixed sentiment around Arrowhead Pharmaceuticals, with both risks and rewards on the table, it makes sense to review the numbers yourself and decide how comfortable you are with the trade off between trial setbacks, funding needs and potential upside. You can then weigh those views against the 2 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals might be on your radar now, but some of the most interesting opportunities often sit just off the main stage, waiting for fresh attention.

Before you move on, take a moment to scan a few focused stock lists on Simply Wall St that can help you round out your watchlist and avoid missing potential standouts.

• Target stability first by reviewing companies in the 74 resilient stocks with low risk scores that may help balance out more volatile positions in your portfolio.
• Spot potential mispricings by checking the 44 high quality undervalued stocks and see which stocks currently line up with stronger fundamentals at a discounted price.
• Get ahead of the crowd by scanning the screener containing 18 high quality undiscovered gems where smaller, less followed stocks with solid numbers could offer fresh ideas before they are widely noticed.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.